<p>12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women</p>

Abstract

PurposeDefine the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP).MethodsTwo years of clinical follow-up data from primary osteoporotic women who had experienced initial osteoporotic vertebral compression fractures (OVCFs) and received PKP plus 12-month TPTD (n=113) or basic treatment (BT) of calcium and vitamin D supplements (n=208) were retrospectively collected. The risk of NVCFs over each 6-month period in the TPTD group was evaluated and compared with the BT group using a logistic regression. Health-related quality of life (HRQoL, EQ-5D questionnaire), back pain [100 mm visual analog scale (VAS)] and bone mineral density (BMD) of the spine were analyzed using linear mixed models for repeated measures (LMMRM).ResultsLogistic regression analysis adjusting for baseline characteristics showed that patients in the TPTD group had a lower risk of NVCFs compared with those receiving BT during the final three observation intervals (6–12 months, OR=0.189, 95% CI=0.030–0.681, p=0.046; 12–18 months, OR=0.009, 95% CI=0.0001–0.111, p=0.001; 18–24 months, OR=0.024, 95% CI=0.0009–0.264, p=0.009, respectively). Significant improvements in adjusted EQ-5D and back pain VAS scores were identified in the TPTD group compared with the BT group, and this improvement was sustained for at least 12 months after teriparatide treatment was discontinued (both p<0.001). The BMD of the spine also showed a higher T-value in the TPTD group compared with the BT group (p<0.001).ConclusionIn routine clinical practice, for patients with OVCFs who receive the PKP procedure, TPTD treatment may be a preferable subsequent therapy because of its ability to reduce the incidence of NVCFs and sustain a high quality of life and back pain alleviation.

The change of sagital balance after PKP for patients with osteoporotic vertebral compression

“…In the previous studies, many reports show that the vertebral body height restoration and kyphotic changes are very significant. As a result, PKP could not only stable the fractured vertebra body and reveal the severe pain immediately, but also restore the vertebral body height and correct the local kyphosis by inflating of the balloon (6,9,10). However, there is no study investigate the influence of PKP on the (12)(13)(14).…”

Factors and Strategies for Post-Vertebroplasty Residual Pain from Thoracolumbar Osteoporotic Vertebral Compression Fractures (OVCF): a systematic review.

“…As all we known, zoledronic acid could inhabit osteoclasts differentiate and proliferate, regulate bone metabolism and reduce bone loss. In this article, 6 retrospective studies [32][33][34][35][36][37] and 2 prospective studies [38,39]were searched out. 7 studies [32][33][34][35][37][38][39] reported the effect of ZOL and one study [37] reported the effect of Teriparatide.1416 cases, 574 cases in test group and 842 cases in control group, who had residual pain in back or low back were observed.…”

<p>Abaloparatide and the Spine: A Narrative Review</p>

“…5,8,[10][11][12][13][14][15][16][17][18][19] Additionally, Kong et al found that patients receiving teriparatide for 12 months after percutaneous kyphoplasty had a lower risk of new vertebral compression fracture and greater improvements in pain and quality of life than placebo at all time points up to 24 months after surgery. 44 While published data has only evaluated teriparatide use in spinal surgery, similar work is ongoing and needed to demonstrate the clinical benefits of abaloparatide.…”